With a prevalence of 2.6–4.5 %, infantile haemangiomas (IH) represent the most common tumour of infancy. While the majority of IH does not require therapy and regresses spontaneously, about 10 % of IH exhibit complications such as obstruction, ulceration or disfigurement. With the advent of oral propranolol, many conventional treatment options have become obsolete. This paper summarizes current recommendations for management of complicated IH. These recommendations have been written by an expert group after a consensus process including bibliographic review, several drafts of synthesis, meetings with quantitative voting system and redaction of an approved final manuscript. Conclusion: Oral propranolol is the first-line agent for the treatment of complicated IH.

Complications, Haemangioma, Infants, Therapy
dx.doi.org/10.1007/s00431-015-2570-0, hdl.handle.net/1765/81623
European Journal of Pediatrics

Hoeger, P.H, Harper, J.I, Baselga, E, Bonnet, D, Boon, L.M, Atti, M.C.D, … Léauté-Labrèze, C. (2015). Treatment of infantile haemangiomas: recommendations of a European expert group. European Journal of Pediatrics (Vol. 174, pp. 855–865). doi:10.1007/s00431-015-2570-0